Latest Tax Incentives News

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Activeport Group Ltd reported a significant $15.7 million net loss for FY25, driven by a $10.9 million goodwill impairment, as it pivots towards recurring software revenue. The company plans a $2.5 million rights issue to support this transition amid ongoing financial challenges.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.

Clever Culture Systems Ltd has reported a remarkable 288% jump in revenue to $6.63 million for the year ended June 2025, turning around from a loss to a net profit of $1.68 million, buoyed by strong product sales and government support.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

RAS Technology Holdings Limited reported a robust 31% revenue increase to $21.3 million in FY25, achieving its first after-tax profit following a strategic acquisition in Hong Kong that expanded its Asian footprint and recurring revenue.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.

Harvest Technology Group reported a reduced net loss of $7.06 million for FY2025 amid restructuring and new funding, while focusing on its remote communications technology segment and launching Project NEON.